VC fund profile · evidence-aware directory data
Sofinnova Crossover II (€725M final close, 2026) stages, portfolio and investment profile
Sofinnova Partners' second life-sciences crossover fund reached a €725M FINAL close announced November 16, 2026. It aims to back about 15 clinical-stage biopharma and medtech companies primarily in Europe, with selective global deals; Hemab, CellCentric and Neurent Medical are named portfolio companies. EIF's 2024 report records a €250M signature associated with the vehicle.
Exact investor check sizes, individual LP terms and the legal closing date are undisclosed.
Keep track of Sofinnova Crossover II (€725M final close, 2026)
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$100K–$1M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Not recorded
Participates: Not recorded
Sector focus
Not recorded
Geography
Paris, France; European and selective global mandate
Founded Not recorded
Fund size / AUM
Not recorded
A separate fund-size evidence record is not yet available.
Portfolio in our directory
None yet
Linked startup profiles
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
Rounds they lead
Rounds they invest
Last verified: 2026-11-16. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.